NEW YORK, NY / ACCESSWIRE / August 11, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Unilever PLC (NYSE:UL)
This lawsuit is on behalf of all persons who purchased or otherwise acquired Unilever American Depositary Receipts between September 2, 2020 and July 21, 2021, inclusive.
Lead Plaintiff Deadline: August 15, 2022

The UL lawsuit alleges Unilever PLC made materially false and/or misleading statements and/or failed to disclose during the class period that: a) in July 2020, the board of Ben & Jerry's, one of Unilever's marquee brands, passed a resolution to end sales of its ice cream in 'Occupied Palestinian Territory' ; and b) this boycott decision risked adverse governmental actions for violations of laws, executive orders, or resolutions aimed at discouraging boycotts, divestment, and sanctions of Israel adopted by 35 U.S. states.

Learn about your recoverable losses in UL: https://www.kleinstocklaw.com/pslra-1/unilever-plc-loss-submission-form?id=30787&from=1

Outset Medical, Inc. (NASDAQ:OM)
This lawsuit is on behalf of all persons or entities who purchased Outset Medical common stock between September 15, 2020, and June 13, 2022.
Lead Plaintiff Deadline: September 6, 2022

The complaint alleges Outset Medical, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's flagship product, Tablo Hemodialysis System ('Tablo'), would require an additional 510(k) application to be filed with The United States Food and Drug Administration ('FDA'), as defendants had 'continuously made improvements and updates to Tablo over time since its original clearance' (2) as a result, the Company could not conduct a human factors study on a cleared device in accordance with FDA protocols; (3) the Company's inability to conduct the human factors study subjected the Company to the likelihood of the FDA imposing a 'shipment hold' and marketing suspension, leaving the Company unable to sell Tablo for home use; and (4) as a result, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and /or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in OM: https://www.kleinstocklaw.com/pslra-1/loss-submission-form-outset-medical-class-action?id=30787&from=1

Enochian BioSciences, Inc. (NASDAQ:ENOB)
Class Period: January 17, 2018 - June 27, 2022
Lead Plaintiff Deadline: September 26, 2022

During the class period, Enochian BioSciences, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's co-founder and inventor Serhat Gumrukcu was engaged in a variety of frauds; (2) Gumrukcu was not a licensed doctor anywhere in the world; (4) as a result of the foregoing, Gumrukcu's purported contributions to the Company lacked a reasonable basis; (5) as a result of the foregoing, the Company had overstated its commercial prospects; (6) Gumrukcu had improperly diverted approximately $20 million from Enochian to entities he owned; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in ENOB: https://www.kleinstocklaw.com/pslra-1/enochian-biosciences-inc-loss-submission-form?id=30787&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm